{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:49:44Z","timestamp":1775587784889,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Long non-coding RNAs musculoaponeurotic fibrosarcoma oncogene family, protein G antisense 1 (lnc-MAFG-AS1) regulates hepatocellular carcinoma (HCC) progression and treatment resistance in multiple ways, while its engagement in HCC clinical management remains obscure. The current study aims to explore the relationship of lnc-MAFG-AS1 with tumor features, liver function indexes, tumor markers, and prognosis in HCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred and fifty-two surgical HCC patients who underwent tumor resection were retrospectively analyzed. Their tumor and adjacent tissues were acquired and then proposed to reverse transcription-quantitative polymerase chain reaction to detect lnc-MAFG-AS1 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lnc-MAFG-AS1 expression was increased in HCC tumor tissue than in adjacent tissue [median (interquartile range): 2.730 (1.685\u20134.198) vs. 0.990 (0.703\u20131.468), <jats:italic>p\u2009<\/jats:italic>&amp;lt;\u20090.001], with a high area under the curve [0.889, 95% confidence interval (CI): 0.854\u20130.924] to distinguish them via receiver operating characteristic curve analysis. Tumor lnc-MAFG-AS1 was linked with multifocal nodules (<jats:italic>p\u2009<\/jats:italic>&amp;lt;\u20090.001), increased Barcelona Clinic Liver Cancer (BCLC) stage (<jats:italic>p\u2009<\/jats:italic>=\u20090.018), and elevated China Liver Cancer (CNLC) stage (<jats:italic>p\u2009<\/jats:italic>=\u20090.008), which also correlated with an abnormal alpha-fetoprotein (AFP) level (<jats:italic>p\u2009<\/jats:italic>=\u20090.004), However, lnc-MAFG-AS1 was not linked with other disease conditions, tumor properties, liver function indexes, or tumor markers (all <jats:italic>p<\/jats:italic>s<jats:italic>\u2009<\/jats:italic>&amp;gt;\u20090.05). In addition, patients with a high expression of lnc-MAFG-AS1 exhibited worse overall survival than those with a low expression of lnc-MAFG-AS1 [median (95% CI): 34.0 (24.5\u201343.5) vs. 48.0 (41.5\u201354.5) months] (<jats:italic>p\u2009<\/jats:italic>=\u20090.011), which was further validated by univariate Cox\u2019s analysis [hazard ratio (HR)\u2009=\u20091.827, <jats:italic>p\u2009<\/jats:italic>=\u20090.013] and multivariate Cox\u2019s analysis (HR\u2009=\u20091.697, <jats:italic>p\u2009<\/jats:italic>=\u20090.040).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lnc-MAFG-AS1 relates to multifocal nodules, increased BCLC stage, elevated CNLC stage, and abnormal AFP level and predicts pejorative prognosis in HCC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.848831","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T06:03:56Z","timestamp":1652767436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long Non-Coding RNA MAFG-AS1 as a Potential Biomarker for Hepatocellular Carcinoma: Linkage with Tumor Features, Markers, Liver Functions, and Survival Profile"],"prefix":"10.3389","volume":"9","author":[{"given":"Yuanyuan","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20418","DOI":"10.18632\/oncotarget.14668","article-title":"The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3760\/cma.j.cn112139-20200803-00605","article-title":"Clinical efficacy and prognostic factors analysis following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging","volume":"59","author":"Li","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular Carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1055\/s-0041-1735528","article-title":"Contemporary algorithm for the management of hepatocellular carcinoma in 2021: the Northwestern approach","volume":"38","author":"Swersky","year":"2021","journal-title":"Semin Intervent Radiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021038813","article-title":"LncRNA MAFG-AS1 upregulates polo-like kinase-1 by sponging miR-505 to promote gastric adenocarcinoma cell proliferation","volume":"31","author":"Fu","year":"2021","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41417-021-00306-8","article-title":"LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1","volume":"29","author":"Bai","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbrc.2021.04.133","article-title":"LncRNA MAFG-AS1 affects the tumorigenesis of breast cancer cells via the miR-574-5p\/SOD2 axis","volume":"560","author":"Dai","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.2147\/CMAR.S274615","article-title":"LncRNA MAFG-AS1 suppresses the maturation of miR-34a to promote glioblastoma cell proliferation","volume":"13","author":"Zhao","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s13577-020-00470-3","article-title":"LncRNA MAFG-AS1 regulates miR-125b-5p\/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells","volume":"34","author":"Tang","year":"2021","journal-title":"Hum Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-022-00455-7","article-title":"LncRNA MAFG-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-3196 and regulating SOX12 expression","author":"Wu","year":"2022","journal-title":"Mol Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3892\/etm.2019.7850","article-title":"Long noncoding RNA MAFG-AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852","volume":"18","author":"Ouyang","year":"2019","journal-title":"Exp Ther Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12131","DOI":"10.26355\/eurrev_202012_24002","article-title":"Long noncoding RNA MAFG-AS1 facilitates the progression of hepatocellular carcinoma via targeting miR-3196\/OTX1 axis","volume":"24","author":"Hu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"688603","DOI":"10.3389\/fcell.2021.688603","article-title":"Long non-coding RNA MAFG-AS1 promotes cell proliferation, migration, and EMT by miR-3196\/STRN4 in drug-resistant cells of liver cancer","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in china (2017 Edition)","volume":"7","author":"Zhou","year":"2018","journal-title":"Liver Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1590\/1806-9282.66.11.1530","article-title":"High-expression of LncRNA MAFG-AS1 is associated with the prognostic of patients with colorectal cancer","volume":"66","author":"Cui","year":"2020","journal-title":"Rev Assoc Med Bras"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-981-10-5203-3_2","article-title":"Long noncoding RNA: genome organization and mechanism of action","volume":"1008","author":"Akhade","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/bs.acc.2019.08.003","article-title":"Long noncoding RNAs in cancer: from discovery to therapeutic targets","volume":"95","author":"Choudhari","year":"2020","journal-title":"Adv Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"765075","DOI":"10.3389\/fphar.2021.765075","article-title":"Long non-coding RNA-mediated competing endogenous RNA networks in ischemic stroke: molecular mechanisms, therapeutic implications, and challenges","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2217\/bmm-2020-0136","article-title":"Long noncoding RNAs as novel biomarkers for Type 2 diabetes","volume":"14","author":"Zhu","year":"2020","journal-title":"Biomark Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10528-021-10138-8","article-title":"The role of long non-coding RNA, nuclear enriched abundant transcript 1 (NEAT1) in cancer and other pathologies","volume":"60","author":"Zhang","year":"2021","journal-title":"Biochem Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/ol.2020.11809","article-title":"Long non-coding RNA GAS5 in human cancer","volume":"20","author":"Yang","year":"2020","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"114657","DOI":"10.1016\/j.bcp.2021.114657","article-title":"MALAT1: a promising therapeutic target for the treatment of metastatic colorectal cancer","volume":"190","author":"Uthman","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12935-020-01669-y","article-title":"MAFG-AS1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost NFIX","volume":"20","author":"Ye","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/15384101.2020.1728017","article-title":"MAFG-AS1 is a novel clinical biomarker for clinical progression and unfavorable prognosis in gastric cancer","volume":"19","author":"Li","year":"2020","journal-title":"Cell Cycle"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1007\/s13577-021-00607-y","article-title":"Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC","volume":"34","author":"Huang","year":"2021","journal-title":"Hum Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2217\/epi-2019-0385","article-title":"Identification of prognostic biomarkers of hepatocellular carcinoma via long noncoding RNA expression and copy number alterations","volume":"12","author":"Du","year":"2020","journal-title":"Epigenomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e21529","DOI":"10.1096\/fj.202002374R","article-title":"HBx-upregulated MAFG-AS1 promotes cell proliferation and migration of hepatoma cells by enhancing MAFG expression and stabilizing nonmuscle myosin IIA","volume":"35","author":"Zhang","year":"2021","journal-title":"FASEB J"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.848831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T14:40:39Z","timestamp":1660228839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.848831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":29,"alternative-id":["10.3389\/fsurg.2022.848831"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.848831","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"848831"}}